ArticleTranslational cancer research2025
TSPAN9 inhibits malignant progression of hepatocellular carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tetraspanins (TSPANs) are a critical family for cell migration, which have been implicated in a variety of activities including cancer. Previous study showed that tetraspanin 9 (TSPAN9) plays an important role in gastric cancer. In this study, we aim to explore the biological functions of TSPAN9 in hepatocellular carcinoma (HCC). Methods: The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) and Gene Expression Profiling Interactive Analysis (GEPIA) databases were used to analyze TSPAN9 expression, prognostic mutations, somatic copy number alterations (sCNAs), and tumor immune characteristics in 33 tumors. Immunohistochemistry images of TSPAN9 in HCC tissues were obtained from the Human Protein Atlas (HPA) database. Survival curves were generated using the Kaplan-Meier Plotter database. The proliferation, migration, and invasion abilities of HCC cells were assessed using Cell Counting Kit-8 (CCK-8), wound healing, and Transwell assays. Results: TSPAN9 was deregulated in various tumor types, and its expression was lower in HCC tissues than that of normal liver tissues (P<0.05). Moreover, TSPAN9 expression had a correlation with the prognosis of tumor patients, and HCC patients with low TSPAN9 expression showed a poor prognosis (Log-rank P<0.05). In addition, we detected that TSPAN9 was significantly decreased in HCC cells (P<0.01). As compared to the control cells, overexpression of TSPAN9 in HCC cells significantly reduced cell proliferation, slowed the wound healing rate, and inhibited the invasive and migration ability (all P<0.05). TCGA database analysis revealed a relationship between the expression of TSPAN9 and epithelium-mesenchymal transformation (EMT) factors. Conclusions: Downregulated expression of TSPAN9 indicates a poor prognosis of HCC patients. TSPAN9 can inhibit the proliferation and metastasis of HCC cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.